Free Trial

United-Guardian Q4 2024 Earnings Report

United-Guardian logo
$8.17 +0.02 (+0.25%)
Closing price 04/11/2025 03:56 PM Eastern
Extended Trading
$8.15 -0.02 (-0.24%)
As of 04/11/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

United-Guardian EPS Results

Actual EPS
$0.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

United-Guardian Revenue Results

Actual Revenue
$2.48 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

United-Guardian Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

United-Guardian's Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Remove Ads

United-Guardian Earnings Headlines

United-Guardian Reports 2024 Financial Results
New “Trump” currency proposed in DC
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
United-Guardian Declares Cash Dividend
United-Guardian Posts Rising Q3 Earnings
See More United-Guardian Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like United-Guardian? Sign up for Earnings360's daily newsletter to receive timely earnings updates on United-Guardian and other key companies, straight to your email.

About United-Guardian

United-Guardian (NASDAQ:UG) manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

View United-Guardian Profile

More Earnings Resources from MarketBeat